By otakuyassine3@gmail.com 
Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) – Equities research analysts at Cantor Fitzgerald lifted their FY2025 earnings per share (EPS) estimates for shares of Stoke Therapeutics in a research note issued to investors on Thursday, March 20th. Cantor Fitzgerald analyst C. Duncan now expects that the company will earn $0.03 per share for the year, up from their previous forecast of ($2.40). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share.
Other analysts have also recently issued reports about the company. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, March 18th. HC Wainwright restated a “buy” rating and set a $47.00 price target on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Finally, Chardan Capital restated a “buy” rating and set a $24.00 price target on shares of Stoke Therapeutics in a report on Wednesday, March 19th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Stoke Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $23.00.
Read Our Latest Research Report on Stoke Therapeutics
Stoke Therapeutics Price Performance
Shares of STOK opened at $8.15 on Monday. The stock has a market capitalization of $431.68 million, a price-to-earnings ratio of -3.88 and a beta of 0.99. Stoke Therapeutics has a 1 year low of $6.29 and a 1 year high of $17.58. The business’s 50 day simple moving average is $9.47 and its 200-day simple moving average is $11.39.
Stoke Therapeutics (NASDAQ:STOK – Get Free Report) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.38. The business had revenue of $22.61 million for the quarter, compared to analysts’ expectations of $4.20 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%.
Insiders Place Their Bets
In other Stoke Therapeutics news, insider Barry Ticho sold 3,884 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the sale, the insider now owns 63,962 shares in the company, valued at $554,550.54. This trade represents a 5.72 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Edward M. Md Kaye sold 10,382 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the sale, the director now owns 148,253 shares in the company, valued at approximately $1,285,353.51. The trade was a 6.54 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 16,532 shares of company stock worth $143,332 over the last quarter. Company insiders own 11.30% of the company’s stock.
Institutional Trading of Stoke Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of STOK. Intech Investment Management LLC purchased a new stake in Stoke Therapeutics in the third quarter worth $160,000. Charles Schwab Investment Management Inc. grew its position in shares of Stoke Therapeutics by 9.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 316,134 shares of the company’s stock worth $3,885,000 after buying an additional 26,870 shares in the last quarter. BNP Paribas Financial Markets grew its position in shares of Stoke Therapeutics by 1,589.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company’s stock worth $936,000 after buying an additional 71,647 shares in the last quarter. Checkpoint Capital L.P. bought a new position in shares of Stoke Therapeutics during the 3rd quarter worth $1,936,000. Finally, RTW Investments LP grew its position in shares of Stoke Therapeutics by 10.1% during the 3rd quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock worth $57,177,000 after buying an additional 427,447 shares in the last quarter.
About Stoke Therapeutics
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.
See Also
Receive News & Ratings for Stoke Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Stoke Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.